Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

D-galactosamine/lipopolysaccharide-induced hepatotoxicity downregulates sirtuin 1 in rat liver: role of sirtuin 1 modulation in hepatoprotection

M. K. Kemelo, L. Wojnarová, N. Kutinová Canová, H. Farghali

. 2014 ; 63 (5) : 615-623. [pub] 20140605

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15036724

D-Galactosamine/Lipopolysaccharide (D-GalN/LPS) is a well known model of hepatotoxicity that closely resembles acute liver failure (ALF) seen clinically. The role of sirtuin 1 in this model has not yet been documented. However, there have been a number of studies about the cytoprotective effects of resveratrol, a SIRT1 activator, in the liver. This study was aimed at elucidating the roles of SIRT1 protein expression or catalytic activity in D-GalN/LPS model of hepatotoxicity. ALF was induced in male Wistar rats by intraperitoneal injection of D-GalN and LPS. Some groups of animals were pretreated with resveratrol and/or EX-527 (SIRT1 inhibitor). The effects of these treatments were evaluated by biochemical and Western blot studies. D-GalN/LPS treatment was able to induce hepatotoxicity and significantly increase all markers of liver damage and lipid peroxidation. A dramatic decrease of SIRT1 levels in response to D-GalN/LPS treatment was also documented. Resveratrol pretreatment attenuated D-GalN/LPS-induced hepatotoxicity. EX-527 blocked the cytoprotective effects of resveratrol. However, both resveratrol and EX-527 pretreatments did not exhibit any significant effect on SIRT1 protein expression. Collectively, these results suggest that downregulation of SIRT1 expression is involved in the cytotoxic effects of D-GalN/LPS model and SIRT1 activity contributes to the cytoprotective effects of resveratrol in the liver.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15036724
003      
CZ-PrNML
005      
20151123141553.0
007      
ta
008      
151120s2014 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.932761 $2 doi
035    __
$a (PubMed)24908092
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Kemelo, M K $u Institute of Pharmacology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. mighty.kemelo@lf1.cuni.cz.
245    10
$a D-galactosamine/lipopolysaccharide-induced hepatotoxicity downregulates sirtuin 1 in rat liver: role of sirtuin 1 modulation in hepatoprotection / $c M. K. Kemelo, L. Wojnarová, N. Kutinová Canová, H. Farghali
520    9_
$a D-Galactosamine/Lipopolysaccharide (D-GalN/LPS) is a well known model of hepatotoxicity that closely resembles acute liver failure (ALF) seen clinically. The role of sirtuin 1 in this model has not yet been documented. However, there have been a number of studies about the cytoprotective effects of resveratrol, a SIRT1 activator, in the liver. This study was aimed at elucidating the roles of SIRT1 protein expression or catalytic activity in D-GalN/LPS model of hepatotoxicity. ALF was induced in male Wistar rats by intraperitoneal injection of D-GalN and LPS. Some groups of animals were pretreated with resveratrol and/or EX-527 (SIRT1 inhibitor). The effects of these treatments were evaluated by biochemical and Western blot studies. D-GalN/LPS treatment was able to induce hepatotoxicity and significantly increase all markers of liver damage and lipid peroxidation. A dramatic decrease of SIRT1 levels in response to D-GalN/LPS treatment was also documented. Resveratrol pretreatment attenuated D-GalN/LPS-induced hepatotoxicity. EX-527 blocked the cytoprotective effects of resveratrol. However, both resveratrol and EX-527 pretreatments did not exhibit any significant effect on SIRT1 protein expression. Collectively, these results suggest that downregulation of SIRT1 expression is involved in the cytotoxic effects of D-GalN/LPS model and SIRT1 activity contributes to the cytoprotective effects of resveratrol in the liver.
650    _2
$a zvířata $7 D000818
650    _2
$a antioxidancia $x farmakologie $7 D000975
650    _2
$a karbazoly $x farmakologie $7 D002227
650    _2
$a cytoprotekce $7 D019610
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a down regulace $7 D015536
650    _2
$a lékové postižení jater $x enzymologie $x etiologie $x patologie $x prevence a kontrola $7 D056486
650    _2
$a inhibitory enzymů $x farmakologie $7 D004791
650    12
$a galaktosamin $7 D005688
650    _2
$a peroxidace lipidů $x účinky léků $7 D015227
650    12
$a lipopolysacharidy $7 D008070
650    _2
$a játra $x účinky léků $x enzymologie $x patologie $7 D008099
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a potkani Wistar $7 D017208
650    _2
$a sirtuin 1 $x antagonisté a inhibitory $x metabolismus $7 D056564
650    _2
$a stilbeny $x farmakologie $7 D013267
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Wojnarová, Lenka $7 _AN073934
700    1_
$a Kutinová-Canová, Nikolína $7 xx0103768
700    1_
$a Farghali, Hassan, $d 1943- $7 jn20000400659
773    0_
$w MED00003824 $t Physiological research Academia Scientiarum Bohemoslovaca $x 1802-9973 $g Roč. 63, č. 5 (2014), s. 615-623
856    41
$u http://www.biomed.cas.cz/physiolres/ $y domovská stránka časopisu
910    __
$a ABA008 $b A 4120 $c 266 $y 4 $z 0
990    __
$a 20151120 $b ABA008
991    __
$a 20151123094944 $b ABA008
999    __
$a ok $b bmc $g 1098012 $s 919911
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 63 $c 5 $d 615-623 $e 20140605 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
LZP    __
$b NLK118 $a Pubmed-20151120

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...